Compare
bioAffinity Technologies, Inc. vs Absci Corp vs OmniAb, Inc. vs iSpecimen Inc.
| Latest fiscal year | bioAffinity Technologies, Inc. BIAF | Absci Corp ABSI | OmniAb, Inc. OABI | iSpecimen Inc. ISPC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $6.16M | $2.80M | $18.67M | $1.93M |
| Revenue growth (YoY) | -34.2% | -38.2% | -29.3% | -79.2% |
| Gross margin | n/a | n/a | n/a | 1.2% (computed) |
| Operating margin | -171.6% | n/m | -369.5% | -465.4% |
| Net margin | -242.0% | n/m | -347.0% | -543.7% |
| Net income | -$14.91M | -$115.18M | -$64.78M | -$10.49M |
| EPS (Diluted) | -$8.66 | -$0.84 | -$0.57 | -$2.28 |
| Operating cash flow | -$9.33M | -$92.92M | -$36.45M | -$4.24M |
| Free cash flow | -$9.39M | -$94.03M | -$37.02M | -$4.24M |
| Cash & equivalents | $6.45M | $20.02M | $25.52M | $6.88M |
| Total assets | $10.96M | $216.30M | $300.91M | $9.53M |
| Total liabilities | $3.68M | $26.85M | $33.89M | $6.44M |
| Shareholders' equity | $7.28M | $189.45M | $267.03M | $3.09M |
| Return on year-end equity | -204.9% | -60.8% | -24.3% | -339.6% |
| Shares outstanding | 4.50M | n/a | 144.31M | 8.48M |
Revenue, most recent five fiscal years
| Fiscal year | bioAffinity Technologies, Inc. | Absci Corp | OmniAb, Inc. | iSpecimen Inc. |
|---|---|---|---|---|
| Latest | $6.16M Ended 2025-12-31 | $2.80M Ended 2025-12-31 | $18.67M Ended 2025-12-31 | $1.93M Ended 2025-12-31 |
| 1 year earlier | $9.36M Ended 2024-12-31 | $4.53M Ended 2024-12-31 | $26.39M Ended 2024-12-31 | $9.29M Ended 2024-12-31 |
| 2 years earlier | $2.53M Ended 2023-12-31 | $5.72M Ended 2023-12-31 | $34.16M Ended 2023-12-31 | $9.93M Ended 2023-12-31 |
| 3 years earlier | $6.90M Ended 2022-12-31 | $4.53M Ended 2022-12-31 | $59.08M Ended 2022-12-31 | $10.40M Ended 2022-12-31 |
| 4 years earlier | n/a | $4.01M Ended 2021-12-31 | $34.75M Ended 2021-12-31 | $11.14M Ended 2021-12-31 |